AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00751296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib bid
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000 mg
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000 mg
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone or prednisolone
Description: Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
Study NCT01972217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone or prednisolone
Description: Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
Study NCT00394095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Oral topiramate 300-400mg/day for 12 weeks
Study NCT00394095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to Experimental arm
Study NCT03248908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pupillary dilation reflex
Description: Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
Study NCT03248908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
Study NCT00577473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
Study NCT01611844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)
Description: 2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right
Study NCT01611844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)
Description: 2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right
Study NCT03234322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: external validated risk prediction model
Description: The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
Study NCT01910298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Reconstruction, Direct to Implant (DTI) with Strattice™
Study NCT01910298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Stage Breast Reconstruction
Study NCT01407432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
Study NCT01407432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of folic acid
Description: Taking of placebo of folic acid by hanging oral route during 3 at 4 months
Study NCT02342808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured center-based lifestyle intervention
Description: Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
Study NCT02342808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education and physician advice
Description: Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
Study NCT04618536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen
Description: Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
Study NCT04618536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic sunscreen
Description: Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
Study NCT04179136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lignan capsules contain 300 mg flaxseed (SDG) extract
Description: lignan capsules contain 300 mg flaxseed (SDG) extract
Study NCT04179136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment matching intervention
Description: Placebo treatment matching intervention
Study NCT02723708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)
Description: During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
Study NCT00625170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10 mg/day for 8 days
Study NCT00625170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: haloperidol 3 mg/day for 8 days
Study NCT01484119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-129968
Description: daily tablets
Study NCT01484119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets and capsules
Study NCT01484119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: daily capsules
Study NCT02667795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitored walking based exercise
Description: Monitored walking based exercise
Study NCT00371150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
Study NCT03005444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10mg/day, for 2 years
Study NCT02345070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR156597
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT02345070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT02345070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT04383600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
Study NCT04422184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Repair and Protect
Description: Dentifricie with NOVAMIN technology
Study NCT04422184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentalclean Daily Regenerator
Description: Dentifricie with Refix technology
Study NCT04422184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentalclean Daily Regenerator with potassium citrate
Description: Dentifricie with Refix technology+ potassium citrate
Study NCT02536976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Study NCT02536976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01742026 — intervention group
Intervention type: PROCEDURE
Intervention: Aspergillus PCR technique
Description: Aspergillus DNA PCR technique
Study NCT01742026 — intervention group
Intervention type: PROCEDURE
Intervention: Aspergillus AGA technique
Description: Aspergillus AGA technique
Study NCT00394017 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Reminder letters
Description: 3 mailed reminder letters
Study NCT00394017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letters
Description: 3 mailed reminder letters
Study NCT03915197 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pneumological evaluation
Description: Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given oral
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given oral
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given orally
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given orally
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study NCT00707083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01580423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125 mg capsule
Study NCT01580423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule identical to aprepitant
Study NCT01533207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Patients followed clinically
Study NCT01533207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01533207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01533207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC)
Study NCT01533207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01533207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT02561884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olostar Tab.
Study NCT02561884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Olmetec and Crestor
Study NCT01287962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: 750 mg，po，QD； 28 days every cycle
Study NCT01287962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po，QD； 28 days every cycle
Study NCT00807508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: wheat meal capsules with each main meal
Study NCT00807508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine
Description: daily leucine capsules with each main meal
Study NCT03593369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (single treatment)+SOC
Description: KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
Study NCT03593369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (consecutive treatments)+SOC
Description: In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
Study NCT03593369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
Study NCT02781714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-way SMS
Description: SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered
Study NCT02993107 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AR101
Description: AR101 powder provided in capsules \& sachets
Study NCT01485029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal (NP) aspirate
Description: Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
Study NCT03304626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 3Mg Capsule
Description: Budesonide capsule in place of prednisone (standard of care)
Study NCT03304626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Prednisone
Description: Prednisone taper (Standard of Care)
Study NCT02365025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meetings guides by experts in sleeping disorders.
Description: meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
Study NCT02739906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone Human Insulin (HinsBet®)
Description: BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
Study NCT02739906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog®)
Description: Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
Study NCT02739906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin (Huminsulin® Normal)
Description: Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
Study NCT00307710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
Study NCT01478529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron OCAS
Description: oral administration
Study NCT04238923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)
Description: Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
Study NCT01148368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fimasartan
Description: single administration of fimasartan 120mg
Study NCT01148368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan
Description: single administration of fimasartan 120mg
Study NCT02242604 — intervention group
Intervention type: OTHER
Intervention: Multidimensional Geriatric Assessment (MGA)
Description: The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)
Study NCT02770014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02987426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented intervention
Description: The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking
Study NCT03656159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral group therapy
Description: Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
Study NCT03656159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non directive support Group
Description: Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
Study NCT03776968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC1119
Description: oral
Study NCT02357654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: single shot of GnRH agonist
Study NCT02357654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03103542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant coagulation factor (rFVIIIFc)
Description: rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously.
Study NCT04494672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with ADAPT system
Description: Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
Study NCT04494672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing without ADAPT system
Description: Intramedullary nailing without ADAPT system